Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Shares notification

31 Jan 2007 09:37

ReNeuron Group plc31 January 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer RENEURON GROUP PLCof existing shares to which voting rights are attached 2. Reason for the notification (please tick the appropriate box or boxes)An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments which may result in theacquisition of shares already issued to which rioting rights are attached An event changing the breakdown of voting rights 3. Full name of person(s) subject to the SAAD INVESTMENTS COMPANY LIMITED notification obligation4. Full name of shareholder(s) (if different from 3.) Vidacos Nominees Ltd (Citigroup Global AWAL)5. Date of the transaction and date on which the Not specified. threshold is crossed or reached6. Date on which issuer notified 30 January 2007 A: Voting rights attached to sharesClass/type Situation Resulting situation after the triggering transaction vi of shares previous to the Triggering if possible transactionusing the ISIN Number of Number Number of Number of voting rights % of voting rightsCODE Shares shares ix of Voting Rights Direct Direct Indirect Direct Indirect Ordinary Shares Not Not 18,950,000 18,950,000 0 15.988% 0 specified specified B: Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration Exercise/Conversion Number of voting rights % of voting date Period/Date that may be acquired if rightsinstrument the instrument is - exercised/converted N/A - - - - Total (A+B)Number of voting rights % of voting rights 18,950,000 15.988% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectivelyheld, if applicable None specified. Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A12. Date on which proxy holder will cease to hold voting N/Arights: 13. Additional information: Recent acquisition. 14. Contact name: Michael Hunt, CEO15. Contact telephone number: 01483 302560 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Jan 20127:00 amRNSWebcast and content of Stem Cell Technical Seminar
11th Jan 201212:20 pmRNSChange of Adviser and Broker
11th Jan 20127:00 amRNSStability of lead stem cell line
9th Jan 201210:00 amRNSReNeuron to present at US healthcare conference
9th Jan 20127:00 amRNSNotification of Stem Cell Technical Seminar
3rd Jan 20127:00 amRNSData confirms pre-clinical efficacy of ReN001
19th Dec 20114:41 pmRNSSecond Price Monitoring Extn
19th Dec 20114:35 pmRNSPrice Monitoring Extension
6th Dec 201110:00 amRNSWelcomes UK Government Life Sciences Strategy
30th Nov 20114:35 pmRNSPrice Monitoring Extension
28th Nov 20117:00 amRNSStroke Update
28th Nov 20117:00 amRNSInterim Results
9th Nov 20117:00 amRNSStroke clinical trial update & notice of results
3rd Nov 20112:54 pmRNSNotification of Major Interest in Shares
1st Nov 20112:13 pmRNSNotification of Interest in Shares
31st Oct 201110:42 amRNSNotification of Major Interest in Shares
22nd Sep 201112:53 pmRNSDirectors' Interest in Shares and Share Options
22nd Sep 201112:48 pmRNSDirectors' Interest in Shares
15th Sep 201110:45 amRNSResults of 2011 Annual General Meeting
15th Sep 20117:00 amRNSAGM Trading Update
1st Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20117:00 amRNSReNeuron receives DSMB clearance
29th Jul 20113:24 pmRNSAnnual Report and Accounts and Notice of AGM
20th Jul 20117:00 amRNSBoard Appointments
5th Jul 20117:00 amRNSContract with Angel Biotechnology Holdings plc
5th Jul 20117:00 amRNSAngel signs new contract with ReNeuron
30th Jun 20117:00 amRNSPreliminary Results
24th Jun 20112:56 pmRNSReNeuron launches new website
16th Jun 20117:00 amRNSLicense agreement with US eye research institute
1st Jun 20119:43 amRNSBlock Listing Six Monthly Review
27th May 20117:00 amRNSNotice of Results and Stroke Clinical Trial Update
28th Apr 201112:22 pmRNSEU legal opinion
8th Apr 20117:00 amRNSManufacturing Agreement
28th Jan 20117:00 amRNSSettlement with Neuralstem, Inc
10th Jan 20112:18 pmRNSTR-1 Notification of major interest in shares
10th Jan 20117:00 amRNSTR-1 Notification of major interest in shares
7th Jan 20117:00 amRNSTR-1: Notification of major interest in shares
4th Jan 20117:00 amRNSMajor Interest in Shares
29th Dec 201011:34 amRNSRESULT OF GENERAL MEETING & THIRD ADMISSION
21st Dec 20107:00 amRNSUpdate on clinical trial
20th Dec 20108:01 amRNSSECOND ADMISSION
17th Dec 20108:01 amRNSFIRST ADMISSION
13th Dec 20107:01 amRNSInterim Results
13th Dec 20107:00 amRNS£10 million Fundraising
1st Dec 20107:00 amRNSBlock Listing Six Monthly Review
17th Nov 20104:41 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
17th Nov 20107:00 amRNSProgress update on ReN009
16th Nov 20107:00 amRNSFirst Patient Treated with ReN001
27th Oct 20107:00 amRNSReNeuron at stem cell and neuroscience conferences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.